Header

Automated storage for experiments

News Archive

Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.

April 2022

StatementApr 19, 2022
Novartis provides more than USD 25 million in medical aid to patients in Ukraine and bordering countries

March 2022

StatementMar 22, 2022
Novartis condemns the war in Ukraine - update March 22
StatementMar 18, 2022
COVID-19 news feed
StatementMar 08, 2022
Novartis expands humanitarian efforts in Ukraine through donation of essential medicines
StatementMar 04, 2022
Novartis condemns the war in Ukraine and commits to supporting humanitarian efforts

February 2022

StatementFeb 15, 2022
Novartis announces European Patent Office orders grant of the European Gilenya® (fingolimod) 0.5mg daily dose patent

January 2022

StatementJan 24, 2022
2021 Global Managed Access Program Community Update

October 2021

StatementOct 01, 2021
Enabling our associates to work safely on our sites

July 2021

StatementJul 20, 2021
Beacon of Hope: Addressing health disparities through holistic community-based collective action

January 2021

StatementJan 15, 2021
Novartis Gene Therapies Recommits to Global Managed Access Program for 2021

September 2020

StatementSep 02, 2020
AveXis renamed Novartis Gene Therapies, signifying the growing importance of gene therapy to Novartis corporate strategy

August 2020

StatementAug 12, 2020
Novartis appoints Marc Boutin as Global Head of Patient Engagement & Advocacy